share_log

Ardelyx | 8-K: Current report

Ardelyx | 8-K: Current report

Ardelyx | 8-K：重大事件
美股SEC公告 ·  08/12 16:09

Moomoo AI 已提取核心訊息

On August 7, 2024, Ardelyx, Inc., a biopharmaceutical company, announced the entry into a Commercial Supply Agreement with Catalent Pharma Solutions, LLC. The agreement, effective as of July 23, 2024, stipulates that Catalent will handle the tableting, testing, release, and bulk packaging of Ardelyx's product, IBSRELA. Ardelyx has committed to purchasing a minimum number of batches of the product annually, with prices subject to annual adjustments based on the producer price index starting January 1, 2025. The agreement also includes maintenance fees and other expenses. The initial term is set to continue until December 31, 2028, with automatic two-year renewals unless terminated by either party. Termination clauses include provisions for material breach and other specified circumstances. The full terms of the Supply Agreement have been filed with the SEC and are incorporated into the Current Report on Form 8-K as Exhibit 10.1.
On August 7, 2024, Ardelyx, Inc., a biopharmaceutical company, announced the entry into a Commercial Supply Agreement with Catalent Pharma Solutions, LLC. The agreement, effective as of July 23, 2024, stipulates that Catalent will handle the tableting, testing, release, and bulk packaging of Ardelyx's product, IBSRELA. Ardelyx has committed to purchasing a minimum number of batches of the product annually, with prices subject to annual adjustments based on the producer price index starting January 1, 2025. The agreement also includes maintenance fees and other expenses. The initial term is set to continue until December 31, 2028, with automatic two-year renewals unless terminated by either party. Termination clauses include provisions for material breach and other specified circumstances. The full terms of the Supply Agreement have been filed with the SEC and are incorporated into the Current Report on Form 8-K as Exhibit 10.1.
2024年8月7日，生物製藥公司ardelyx與Catalent Pharma Solutions簽署了商品供應協議。協議於2024年7月23日生效，規定Catalent將負責ardelyx產品IBSRELA的壓片、檢測、發佈和散裝包裝。ardelyx已承諾每年購買一定數量的產品，價格將根據生產者物價指數自2025年1月1日起進行年度調整。協議還包括維護費用和其他費用。初始期限設定爲2028年12月31日，自動續約兩年，除非任何一方終止。終止條款包括重大違約和其他特定情況。供應協議的全部條款已提交給SEC，並作爲表格8-k的展示10.1。
2024年8月7日，生物製藥公司ardelyx與Catalent Pharma Solutions簽署了商品供應協議。協議於2024年7月23日生效，規定Catalent將負責ardelyx產品IBSRELA的壓片、檢測、發佈和散裝包裝。ardelyx已承諾每年購買一定數量的產品，價格將根據生產者物價指數自2025年1月1日起進行年度調整。協議還包括維護費用和其他費用。初始期限設定爲2028年12月31日，自動續約兩年，除非任何一方終止。終止條款包括重大違約和其他特定情況。供應協議的全部條款已提交給SEC，並作爲表格8-k的展示10.1。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間